International Urogynecology Journal

, Volume 30, Issue 11, pp 1879–1886 | Cite as

Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?

  • Anastasios TranoulisEmail author
  • Dimitra Georgiou
  • Lina Michala
Original Article


Introduction and hypothesis

Fractional CO2 and vaginal erbium lasers have emerged as potential treatment options for genitourinary syndrome of menopause (GSM) in breast cancer (BC) survivors.


We conducted a systematic review of the literature to ascertain whether available evidence supports the efficacy and safety of laser treatment for GSM in BC patients. MEDLINE, Scopus and Cochrane Library databases were systematically searched from inception until March 2019 for studies on laser treatment for GSM in BC patients.


We yielded six observational studies meeting the inclusion criteria. The studies were of moderate quality. Taken together, the studies suggest that laser treatment may significantly alleviate or resolve the GSM-related symptoms and improve sexual function. Furthermore, a significant increase of the vaginal health index was reported. Positive effect was maintained up to 12 months. The safety and tolerability profile is encouraging, given that no adverse effects were reported, while only few patients discontinued laser treatment, owing to reported discomfort.


Our findings suggest that lasers appear to be effective and practical treatment options in BC survivors suffering from GSM. Evidence concerning long-term effects is lacking. The rationale for repeated treatment remains uncertain. Randomized controlled trials that collate different frequencies, intensities and durations are warranted to ascertain a dose-response relationship and adherence.


Genitourinary syndrome of menopause Vaginal atrophy Laser Breast cancer 



We certify that no party has a direct interest in the results of the research and that no benefit will be conferred to us or any organization with which we are associated.

Compliance with ethical standards

Conflicts of interest


Details of ethics approval

None needed, as this is a systematic review.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefGoogle Scholar
  2. 2.
    Howlade N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2008. Bethesda: National Cancer Institute; 2011.Google Scholar
  3. 3.
    Guo F, Kuo YF, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124:3500–9.CrossRefGoogle Scholar
  4. 4.
    Sousa MS, Peate M, Jarvis S, Hickey M, Friedlander M. A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol. 2017;9:269–85.CrossRefGoogle Scholar
  5. 5.
    Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66:43–73.CrossRefGoogle Scholar
  6. 6.
    Palma F, Volpe A, Villa P, Cagnacci A. Vaginal atrophy of women in potmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–4.CrossRefGoogle Scholar
  7. 7.
    Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015;5:50–66.CrossRefGoogle Scholar
  8. 8.
    Biglia N, Bounous VE, D’Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17:611–7.CrossRefGoogle Scholar
  9. 9.
    Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the quality of adjuvant endocrine therapy delivery for breast cancer in United States. JAMA Oncol. 2017;3:928–35.CrossRefGoogle Scholar
  10. 10.
    Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19.CrossRefGoogle Scholar
  11. 11.
    Faubion SS, Stuenkel CA, Chism LA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women’s. Sexual Health Menopause. 2018;25:596–608.PubMedGoogle Scholar
  12. 12.
    ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127:93–96.Google Scholar
  13. 13.
    Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25:21–8.CrossRefGoogle Scholar
  14. 14.
    Qureshi AA, Tenenbaum MM, Myckatyn TM. Nonsurgical vulvovaginal rejuvenation with radiofrequency and laser devices: a literature review and comprehensive update for aesthetic surgeons. Aesthet Surg J. 2018;38:302–11.CrossRefGoogle Scholar
  15. 15.
    Liberati A, Altman DG, Tetzlaff J, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:1–34.CrossRefGoogle Scholar
  16. 16.
    Lim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712Y716.CrossRefGoogle Scholar
  17. 17.
    Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363–9.CrossRefGoogle Scholar
  18. 18.
    Gittens P, Mullen G. The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. J Cosmet Laser Ther. 2018;8:1–5.Google Scholar
  19. 19.
    Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci. 2018;33:1047–54.CrossRefGoogle Scholar
  20. 20.
    Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause. 2018;25:657–62.CrossRefGoogle Scholar
  21. 21.
    Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24:316–9.CrossRefGoogle Scholar
  22. 22.
    Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294:841–6.CrossRefGoogle Scholar
  23. 23.
    Mothes AR, Runnenbaum M, Runnenbaum IB. Ablative dual-phase erbium: YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol. 2018;144:955–60.CrossRefGoogle Scholar
  24. 24.
    Derzko C, Elliot S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14:20–40.CrossRefGoogle Scholar
  25. 25.
    Salvatore S, Leone Roberti Maggiore U, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22:845–9.CrossRefGoogle Scholar
  26. 26.
    Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2017;25:21–8.CrossRefGoogle Scholar
  27. 27.
    Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of erbium: YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2017;49:160–8.CrossRefGoogle Scholar
  28. 28.
    Flint R, Cardoso T, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO2 laser versus non-ablative erbium : YAG laser for the treatment of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial. Climacteric. 2019;24:1–5.Google Scholar

Copyright information

© The International Urogynecological Association 2019

Authors and Affiliations

  • Anastasios Tranoulis
    • 1
    Email author
  • Dimitra Georgiou
    • 2
  • Lina Michala
    • 3
  1. 1.Department of Obstetrics and Gynaecology, Guy’s and St Thomas’ NHS FoundationKing’s CollegeLondonUK
  2. 2.Department of Obstetrics and Gynaecology, Chelsea and Westminster NHS TrustImperial CollegeLondonUK
  3. 3.First Department of Obstetrics and Gynaecology, Alexandra HospitalNational and Kapodistrian University of Athens, School of MedicineAthensGreece

Personalised recommendations